Overview
SwissADME is a web tool that calculates molecular parameters in relation with pharmacokinetics and dynamics properties, as stated in its own site description. It is operated by the Molecular Modelling Group of the University of Lausanne together with the SIB Swiss Institute of Bioinformatics, and users submit a list of SMILES to obtain per-molecule reports.
The site carries a Terms of Use page and a help/FAQ section, and belongs to the Swiss family of web tools (SwissDock, SwissTargetPrediction and others). A notice on the site records that the tool was modified (mid-May) to stop relying on a commercial chemistry toolkit whose academic support ended, while stating that the underlying technologies and parameters were not changed.
SwissADME is a hosted service: no source repository is published through this entry, no API is documented, and submitted molecules are subject to the site's terms of use. Computed values are model-based estimates for triage and teaching, not experimental measurements.
Key Features
- Web interface accepting a list of SMILES for batch property calculation.
- Physicochemical descriptors, pharmacokinetics- and dynamics-related parameters and druglikeness indicators presented in a per-molecule report.
- Part of the Swiss web-tool family operated with the SIB Swiss Institute of Bioinformatics.
Use Cases
- Profile small compound sets during early drug-discovery triage without installing software.
- Compare computed ADME-related parameters across candidate molecules in teaching or discussion settings.
How to Use
Enter a list of SMILES on the site and read the generated per-molecule report. The tool is web-only; results depend on the models the operators run, and the site's terms of use apply to submitted data. See: https://www.swissadme.ch/
Sources and verification
This entry describes capabilities documented by the linked project sources. Catalog edits are not evidence of a successful run, compatibility test or scientific performance evaluation.
Repository source reviewed for this catalog version:
Read the editorial and verification policy